Afatanib benefit in uncommon EGFR mutation-positive NSCLC acknowledged
13 Aug 2019
Sponsored by Boehringer Ingelheim Pty Ltd
The Giotrif (afatinib) approved product information has been updated to incorporate data on efficacy in patients with non-squamous non-small cell lung carcinoma (NSCLC) harbouring uncommon EGFR mutations.1 Afatinib is a second-generation EGFR TKI, which irreversibly blocks signaling from all homo- and heterodimers formed by the ErbB family members EGFR, HER2, ErbB3 and ErbB4. It is ...